Reported Earlier, Perspective Therapeutics Says Bamzireotide Delivers 37% ORR In All 68 Treated NET Patients, 91% Disease Control, Median Follow-Up Up To 128 Weeks; Grade 3 TEAEs In 29%, No Grade 4 Or 5 Events
Benzinga Newsdesk 10 hours ago
News
Additional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior findings of durable ongoing disease control and encouraging responses in all three cohorts across multiple patient
- Additional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior findings of durable ongoing disease control and encouraging responses in all three cohorts across multiple patient populations
- Preliminary evidence of more robust anti-tumor activity and durable responses in GEP-NET patients whose target lesions all express SSTR2+ supports focusing on this population
- Bamzireotide continues to be well-tolerated
- Targeting End-of-Phase 2 meeting in 1Q 2027